Stephen Straubing, MD
Addiction Medicine · Gainesville, FLNPI 1184674848
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alkermes, Inc. accounts for 89.6% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $115 and has fallen 84.4% since, to $18 in 2025. That places this record below the midpoint for addiction medicine clinicians in FL, where the typical reported total is $254.
Across 9 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$154
- Indivior Inc.$18
Across 150 payments — averaging $1668.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$118K
- Pfizer$68K
- AstraZeneca$37K
- Astrazeneca UK Limited$14K
- Boehringer Ingelheim International GmbH$9K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
What the payments were for
- Food & beverage$172100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 8 | $154 |
| Indivior Inc. | 1 | $18 |
How this compares
$172 in reported general payments places this provider in the 35th percentile of 101 addiction medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 21 | $4,726 |
| Buprenorphine Hcl | 66 | $2,256 |
| Clonazepam | 12 | $151 |
| Sertraline Hcl | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Gainesville
- Mark GoldGainesville$355K
- Gabriel PaulianGainesville$3K
- John AbernethyGainesville$617
- Sarah DooleyGainesville$424
- Jason HuntGainesville$336
- Mark JacksonSaint Augustine$225K
- David KirbyLake City$183K
- George SchroederOrmond Beach$68K
- Brian GadboisTampa$50K
- Timothy GoodenNavarre$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.